N/A N=12 Erectile Rating During the Treatment of Rectal Cancers Localized
Rectal Cancer Stage I
Primary: Proportion of Patients With Erectile Dysfunction Induced by Medical and Surgical Treatment of Rectal Cancer — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=618 Treatment of Erectile Dysfunction I
Erectile Dysfunction
Primary: Change in Erectile Function Domain Assessed by International Index of Erectile Function (IIEF), Baseline to Final Visit/Week 12, mITT (Modified Intent-to-Treat), LOCF…
Phase 3 N=70 Botulinum Toxin for Erectile Dysfunction
Sexual Dysfunction · Erectile Dysfunction
Primary: Right (PSV R) and Left (PSV L) Cavernosal Artery Mean PSV Before Treatment — 34.52; 30.85; 34.33; 31.73 cm/sec
Phase 3 N=601 Treatment of Erectile Dysfunction II
Erectile Dysfunction
Primary: Change in Erectile Function Domain Assessed by International Index of Erectile Function (IIEF), Baseline to Final Visit/Week 12, mITT (Modified Intent-to-Treat), LOCF…
N/A N=103 Safety and Efficacy of Low Intensity Shockwave for the Treatment of Erectile Dysfunction
Vasculogenic Erectile Dysfunction
Primary: International Index of Erectile Function (IIEF-EF) Questionnaire — 18; 17.9; 20.5; 19.7 score on a scale — p=<0.007
Phase 3 N=27 COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure
Heart Failure · Heart Failure, Systolic · Erectile Dysfunction
Primary: Erectile Function Score Using Index of Erectile Function (IIEF-15) — 15.1; 12.2 Scores on a scale — p=0.3432
Phase 4 N=140 Effect of Testosterone in Men With Erectile Dysfunction
Erectile Dysfunction · Testosterone Deficiency · Diabetes
Primary: Change From Baseline in Erectile Function Domain Score of the International Index of Erectile Function (IIEF) — 19.6; 20.1; 21.3; 21.3 units on a scale
N/A N=20 MED3000 Topical Gel for On-Demand Treatment of Post-Radical Prostatectomy Erectile Dysfunction
Erectile Dysfunction Following Radical Prostatectomy
Primary: Whether the Erectile Function Domain of the International Index of Erectile Function Mean Change From Baseline Met or Exceeded the Minimally Clinically Important…
Phase 4 N=623 A Study in Erectile Dysfunction
Erectile Dysfunction
Primary: Percentage of Participants Having an International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 Through 12-Week…
Phase 2 N=26 Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for ED
Erectile Dysfunction
Primary: Number of Participants With Adverse Experiences as Measured by Changes in Physical Examination of the Penis — 0; 0; 0 Participants
Phase 3 N=117 Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
Alopecia
Primary: Number of Participants With Adverse Events (AE) Related to Sexual Function in the Double-blind Treatment Period — 5; 9 Participants — p=0.27
Phase 2 N=61 Safety and Efficacy of Autologous Platelet-Rich Plasma for Erectile Dysfunction.
Erectile Dysfunction
Primary: Number of Participants Achieving MCID in IIEF-EF. — 14; 15; 10; 13 Participants
Phase 4 N=372 A Study in Erectile Dysfunction
Erectile Dysfunction
Primary: Earliest Onset Day Measured by Cumulative Percentage of Participants With Yes Response to Sexual Encounter Profile Diary Question 3 — 54.5; 62.2; 47.2; 49.1 cumulative…
Phase 3 N=290 Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer
Prostate Cancer · Erectile Dysfunction
Primary: Assessment of Erectile Dysfunction — 64; 64; 59.00; 58 units on a scale
N/A N=98,832 Identification of Underlying Conditions in Men Prescribed a PDE5 Inhibitor
Erectile Dysfunction · Cardiovascular Diseases · Male Urogenital Diseases
Primary: Percentage of Participants With Underlying Condition Until Day -1 of the Index PDE5i Prescription — 70.23; 55.73 Percentage of participants — p=<0.001
Phase 2 N=894 A Study of LY900010 in Erectile Dysfunction
Erectile Dysfunction
Primary: Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain Score — 2.515; 2.405; -0.971; 3.530 units on a…
Phase 3 N=298 Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy
Erectile Dysfunction
Primary: Change in Percentage of Sexual Attempts in Which Subjects Are Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse — 13.9; 28.0; 29.4…
Phase 3 N=192 Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction
Erectile Dysfunction
Primary: Change From Baseline in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF) Questionnaire, in Patients Randomised to MED3000, at…
Phase 2 N=14 Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer
Male Erectile Disorder · Prostate Adenocarcinoma · Erectile Dysfunction, CTCAE
Primary: Change in International Index of Erectile Function (IIEF) Scores — 0; 0; 0 Participants
Phase 2 N=20 Mirabegron For Erectile Dysfunction
Erectile Dysfunction · Overactive Bladder · Urinary Incontinence
Primary: Erectile Function Assessed by IIEF Questionnaire — 12.7 score on a scale
Phase 3 N=74 An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms
Erectile Dysfunction · Lower Urinary Tract Symptoms
Primary: Change From Baseline Erectile Function Domain of the International Index of Erectile Function — 2.84; 2.84 Change in EF Domain Score from Baseline
Phase 2 N=135 Vessel Sparing Prostate Radiation Therapy
Cancer of the PROSTATE
Primary: The Percentage of Patients Able to be Sexually Active With or Without the Use of Aids — 88 percentage of patients
N/A N=80 Radial Shockwave Therapy for Erectile Dysfunction
Erectile Dysfunction
Primary: Change IIEF-EF Score — 3.4; 4.2 units on a scale
Phase 4 N=24 Testosterone for Peripheral Vascular Disease
Hypogonadism · Peripheral Vascular Disease · Type 2 Diabetes
Primary: Change in Arterial Stiffness — 15.02; 15.08; 14.08; 16.12 index β
Phase 4 N=176 Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied
Impotence
Primary: Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Index at the End of the DB Treatment (Week 8) — 80.27; 62.15 scores on a scale — p=<0.0001
Phase 4 N=15 Effect of Prolonged PDE-5 Inhibition on Insulin Signaling in Skeletal Muscle.
Metabolic Syndrome
Primary: Insulin-stimulated AKT Phosphorylation — 0.065; -0.457 change in ratio
Phase 2 N=76 A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels
Ejaculatory Dysfunction · Hypogonadism
Primary: Change From Baseline in the Male Sexual Health Questionnaire-Ejaculatory Dysfunction-Short Form (MSHQ-EjD-SF) Ejaculatory Function Score at 16 Weeks — 3.61; 2.95 units…
Phase 2 N=125 PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction
Healthy · Obese
Primary: Resting Energy Expenditure After 12 Weeks of Drug Therapy (kcal/Day) — 1267; 1268 kcal/day
N/A N=20 Penile Nerve Stimulation for Treatment of Delayed Ejaculation
Delayed Ejaculation
Primary: International Index of Erectile Function (IIEF) Scale Score — 7.5; 9.7 score on a scale
Phase 4 N=440 Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
Erectile Dysfunction
Primary: Per-subject Proportion of Sexual Attempts That Had an Erectogenic Effect Within Approximately 15 Minutes Following Dosing — 14.9; 25.9; 29.1 percentage of successes